SCHEDULE 13G/A: RA Capital Management Group Reports Full Divestment of C4 Therapeutics Stake

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of C4 Therapeutics, Inc. as of March 31, 2025.

Summary

• This document is an Amendment No. 1 to a Schedule 13G filing concerning C4 Therapeutics, Inc.'s Common Stock.
• The reporting persons are RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P.
• As of March 31, 2025, all listed reporting persons beneficially own 0.00 shares of C4 Therapeutics, Inc., representing 0.0% of the class.
• This filing signifies a complete divestment of their previous holdings in C4 Therapeutics, Inc.
• The reporting persons explicitly state that they disclaim status as a 'group' for the purposes of this Schedule 13G.

Sentiment

Score: 3

Explanation: The document reports a complete divestment by a significant institutional investor, which is generally perceived as a negative signal for the company's stock, indicating a lack of confidence or a strategic shift by the investor.

Negatives

• RA Capital Management, L.P. and its affiliates have fully divested their beneficial ownership in C4 Therapeutics, Inc., now holding 0.0% of the common stock. This complete exit by a significant institutional investor could be interpreted negatively by the market.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Existing shareholders may react negatively to the news of a significant institutional investor fully divesting its stake, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

Keywords

C4 Therapeutics, RA Capital Management, Schedule 13G, beneficial ownership, divestment, institutional investor, common stock, SEC filing